Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy

Inclusion Criteria: * A diagnosis of idiopathic SFN (based on clinical and electrodiagnostic criteria). * Each day for 7 days prior to Visit 2 (Washout) they must complete a modified Quadruple Visual Analogue Scale₁ showing moderate to severe pain (i.e. a daily mean rating score of ≥ 4). * As the safety of pregabalin in pregnancy has not been established, females of childbearing potential must have a negative βHCG serum and agree to practice acceptable birth control methods. * All subjects must have screening laboratory values that are within normal limits or abnormal values that are deemed not clinically significant by the Principle Investigator. Exclusion Criteria: * Have a psychological or psychiatric condition that may hinder their ability to provide important information * History of psychosis, drug or alcohol abuse history within the last year * Malignancy within the last 2 years (except skin cancer) * Clinically significant conditions (including but not limited to cardiovascular or hepatic diseases), and seizure disorders. * Subjects with an abnormal 2-hour glucose tolerance test (i.e., glucose \>7.8 mmol/l) will be excluded under "clinically significant conditions" as stated above. * May not have participated in a previous trial of pregabalin, have a history of intolerance or hypersensitivity to pregabalin. * Patients with renal impairment (CrCl \< 60 ml/min) will be excluded.